Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

NCT07118696 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary TB

Interventions

DRUG: Extra 600mg of Rifampicin
DRUG: Placebo

Sponsor

Hamilton Health Sciences Corporation

Collaborators

[object Object]
[object Object]